These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36705879)

  • 1. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
    Hines JB; Kacew AJ; Sweis RF
    Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting STING for cancer immunotherapy: From mechanisms to translation.
    Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
    Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
    Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity.
    Tabar MMM; Fathi M; Kazemi F; Bazregari G; Ghasemian A
    Mol Biol Rep; 2024 Apr; 51(1):487. PubMed ID: 38578532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects.
    Wang B; Yu W; Jiang H; Meng X; Tang D; Liu D
    Front Immunol; 2024; 15():1485546. PubMed ID: 39421752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.
    Luo K; Li N; Ye W; Gao H; Luo X; Cheng B
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer.
    Alnukhali M; Altabbakh O; Farooqi AA; Pollack A; Daunert S; Deo S; Tao W
    Curr Med Chem; 2024; 31(40):6556-6571. PubMed ID: 38347787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into the dichotomous regulation of STING activation in immunotherapy.
    Hu Z; Yang Y; Fang L; Zhou J; Zhang H
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
    Zhang J; Yu S; Peng Q; Wang P; Fang L
    Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the promise of systemic STING agonist for cancer immunotherapy.
    Sun X; Zhou X; Lei YL; Moon JJ
    J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated patent review of stimulator of interferon genes agonists (2021 - present).
    Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
    Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Damage and Cancer Immunotherapy: A STING in the Tale.
    Reisländer T; Groelly FJ; Tarsounas M
    Mol Cell; 2020 Oct; 80(1):21-28. PubMed ID: 32810436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy.
    Chen S; Peng A; Chen M; Zhan M
    Front Oncol; 2022; 12():1093240. PubMed ID: 36741735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
    Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
    Li A; Yi M; Qin S; Song Y; Chu Q; Wu K
    J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.